Market Place
Sourcing Support
Nippon Shinyaku & Atsena Partner on ATSN-101 in U.S. & Japan
13 Nov 2024 //
GLOBENEWSWIRE
NS Pharma`s Galactic53 Trial Data Is Published in Scientific Reports
15 Oct 2024 //
PR NEWSWIRE
Capricor sells Europe rights to DMD therapy for $35M FDA application approaches
19 Sep 2024 //
FIERCE BIOTECH
Capricor Signs Term Sheet With Nippon Shinyaku for Europe
17 Sep 2024 //
GLOBENEWSWIRE
NS-050/NCNP-03 Gets FDA Rare Pediatric Disease Designation
10 Sep 2024 //
PR NEWSWIRE
MiNA Collaboration with Nippon to Develop RNAa Therapeutics Targeting
04 Apr 2024 //
BUSINESSWIRE
Japanese pharma firm Eli Lilly, Nippon Shinyaku join hands haematologic oncology
28 Mar 2024 //
BIOSPECTRUM ASIA
The Menarini Group Announces ELZONRIS Designated as an Orphan Drug for BPDCN
30 Aug 2023 //
BUSINESSWIRE
Japan approves iron deficiency drug from Pharmacosmos
29 Mar 2022 //
MEDWATCH
Nippon Shinyaku Establishes a Local Subsidiary in Tianjin, China
26 Jan 2022 //
PRESS RELEASE
Capricor Tx, Nippon Shinyaku Partner for CAP-1002 in DMD
25 Jan 2022 //
GLOBENEWSWIRE
Nippon Shinyaku, Dynacure partner to develop & commercialize DYN101 in Japan
11 Nov 2021 //
PHARMABIZ
Menarini Group and Nippon Shinyaku Enter into an Exclusive License Agreement
29 Mar 2021 //
PRNEWSWIRE
Nippon Shinyaku’s DMD Drug Gets Orphan Status in Europe
09 Jun 2020 //
JIHO
Nippon Shinyaku inks new agreement for prostate cancer treatment
12 Feb 2020 //
BIOSPECTRUMASIA
Chugai, Nippon Shinyaku bring Gazyva in Japan
31 Aug 2018 //
BIOSPECTRUM
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.